From Wikipedia, the free encyclopedia
Jump to: navigation, search
Palonosetron structure.svg
Systematic (IUPAC) name
Clinical data
AHFS/ monograph
MedlinePlus a610002
Licence data US FDA:link
  • AU: B1
  • US: B (No risk in non-human studies)
Legal status
Routes of
Intravenous, oral
Pharmacokinetic data
Bioavailability 97% (oral)
Protein binding 62%
Metabolism Hepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
Biological half-life Approximately 40 hours
Excretion Renal, 80% (of which 49% unchanged); fecal (5 to 8%)
CAS Registry Number 135729-61-2 N
ATC code A04AA05
PubChem CID: 148211
DrugBank DB00377 YesY
ChemSpider 4892289 YesY
UNII 5D06587D6R YesY
ChEBI CHEBI:85161 YesY
Chemical data
Formula C19H24N2O
Molecular mass 296.407 g/mol
 N (what is this?)  (verify)

Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there are tentative data to suggest that it may be better than granisetron.[1]

Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy,[2] or as a single oral capsule one hour before chemotherapy.[3] The oral formulation was approved on August 22, 2008 for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV.[3]

See also[edit]


  1. ^ Billio, A; Morello, E; Clarke, MJ (Jan 20, 2010). "Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.". The Cochrane database of systematic reviews (1): CD006272. doi:10.1002/14651858.CD006272.pub2. PMID 20091591. 
  2. ^ De Leon A (2006). "Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting". Proceedings (Baylor University. Medical Center) 19 (4): 413–6. PMC 1618755. PMID 17106506. 
  3. ^ a b Waknine, Yael (September 4, 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. Retrieved 2008-09-04.  Freely available with registration.